Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

5.20USD
22 Nov 2017
Change (% chg)

$-0.17 (-3.26%)
Prev Close
$5.38
Open
$5.35
Day's High
$5.40
Day's Low
$5.18
Volume
119,064
Avg. Vol
264,264
52-wk High
$21.15
52-wk Low
$2.80

Chart for

About

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $157.75
Shares Outstanding(Mil.): 30.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Otonomy reports third quarter loss of $0.69 per share

* Otonomy reports third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease

Nov 08 2017

BRIEF-Otonomy Inc says ‍non-commercial workforce reduced by one-third​

* Otonomy Inc - ‍* non-commercial workforce reduced by one-third​

Sep 13 2017

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc said on Wednesday it suspended developing its drug for Meniere's disease, a chronic disorder of the inner ear, after it failed a late-stage trial, sending the drugmaker's shares plummeting in premarket trade.

Aug 30 2017

BRIEF-Otonomy reports results for Averts-1 phase 3 trial for Otividex

* Says ‍company is withdrawing spending guidance for year pending review of product pipeline plans

Aug 30 2017

Otonomy's ear disease drug fails late-stage study

Aug 30 U.S. drugmaker Otonomy Inc said on Wednesday its drug to treat Ménière's disease, a chronic disorder of the inner ear, missed the main goal in a late-stage study.

Aug 30 2017

BRIEF-Otonomy ‍reaffirms qtrly ‍net loss per share $0.77​

* Otonomy reports second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-FDA accepts Otonomy's expanded label application for Otiprio

* Otonomy announces FDA acceptance of Otiprio supplemental new drug application filing for acute otitis externa

Jul 18 2017

BRIEF-Otonomy announces successful end-of-phase 2 review by FDA for Otiprio

* Otonomy announces successful end-of-Phase 2 review by FDA for Otiprio® in acute otitis media with tympanostomy tubes

Jun 22 2017

Earnings vs. Estimates